Selective Therapeutic Potential of a H2O2-Inducible DNA Interstrand Cross-linker in Anaplastic Thyroid Carcinoma

Chenghui Lu1,2, Dehao Yu3, Xufu Wang2

  • 1Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, P. R. China.

Endocrinology
|February 14, 2025
PubMed

Insights

Hydrogen peroxide-inducible DNA interstrand cross-link (HP-ICL) effectively targets anaplastic thyroid cancer (ATC) by exploiting higher H2O2 levels. This novel therapy shows significant in vitro and in vivo efficacy, inhibiting tumor growth and inducing apoptosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Anaplastic thyroid cancer (ATC) exhibits elevated hydrogen peroxide (H2O2) levels compared to normal thyroid cells.
  • Targeting cellular H2O2 levels presents a potential therapeutic strategy for ATC.

Purpose of the Study:

  • To investigate the efficacy of hydrogen peroxide-inducible DNA interstrand cross-link (HP-ICL) as a targeted therapy for ATC.
  • To evaluate the in vitro and in vivo effects of HP-ICL on ATC cell viability, apoptosis, DNA damage, and key signaling pathways.

Main Methods:

  • In vitro studies involved assessing H2O2 levels, cell viability (MTT), apoptosis, cell cycle, DNA damage (γH2AX assay), and protein expression (Western blotting) in ATC cells treated with HP-ICL.
  • In vivo efficacy was evaluated using an ATC xenograft mouse model, monitoring tumor growth, body weight, and organ damage.

Main Results:

  • HP-ICL treatment significantly reduced ATC cell viability, increased apoptosis, and induced G2/M phase arrest.
  • HP-ICL elevated DNA damage markers (γH2AX), modulated apoptosis-related proteins (Bcl-2, Bax, cleaved-Caspase 3, PARP), and inhibited the PI3K/AKT/mTOR pathway.
  • In vivo, HP-ICL suppressed tumor growth, with reduced proliferation markers (Ki67) and inhibited signaling pathways in tumor tissues, without significant toxicity.

Conclusions:

  • HP-ICL demonstrates potent anti-cancer activity against ATC both in vitro and in vivo.
  • The findings suggest HP-ICL is a promising targeted therapeutic agent for anaplastic thyroid cancer.